top of page
scientific evidence
The original research done by Australian scientists, leaded by Dr. Timothy Davis and Richard Lispscombe from Proteomics International, which shows the process of the discovery of specific biomarkers that are used in the Algorithm used in INNOVATIO ND2 (PromarkerD).
The largest VALIDATION study done with a global pharmaceutical company, Janssen, which corroborates the predictive power of the biomarkers used in the algorithm PromarkerD (INNOVATIO ND2) to identify and classify the risk of developing diabetic nephropathy.
This report is an example of the cross validation done to demonstrate the technical equivalency (then clinical) between the mass spectrometry and ELISA platforms.
ADA 2021
economy model
During 2021 ADA meeting , this health economic model was presented to show the potential US$ millions in savings after adopting these biomarkers to identify patients at risk of developing Renal Disease, implement clinical interventions to avoid becoming renal patients in the future.
In this study it can be observed how the use of drugs of the class Sodium transport protein 2 (SLGT2) inhibitors such as Canagliflozin significantly decreases the risk score of INNOVATIO ND2 (PromarkerD), compared to placebo over 3 years .
bottom of page